Should You Buy Ginkgo Bioworks Holdings Inc (DNA) Stock Friday Morning? (2024)

FAQs

Is DNA stock a good buy today? ›

The highest analyst price target is $3.00 ,the lowest forecast is $1.10. The average price target represents 82.88% Increase from the current price of $1.11. Ginkgo Bioworks Holdings's analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.

Based on short-term price targets offered by five analysts, the average price target for Ginkgo Bioworks Holdings, Inc. comes to $1.92. The forecasts range from a low of $1.00 to a high of $3.00. The average price target represents an increase of 128.57% from the last closing price of $0.84.

For 2024, it aims to onboard as many as 120 additional programs, generating as much as $235 million in total revenue in the process. The demand for its services is clearly there, so it is probable that it will hit its target.

Based on 13 analysts tracking and researching Ginkgo Bioworks Holdings Inc (DNA) share have buy recommendation on an average.

What investors especially disliked about Ginkgo's Q4 update. It's not surprising that Ginkgo Bioworks' shares fell after the company missed estimates on the top and bottom lines. However, the biggest problem with its fourth-quarter update was its full-year 2024 guidance.

Stock Prediction 2025. The Ginkgo Bioworks Holdings, Inc. stock prediction for 2025 is currently $ 0.655215, assuming that Ginkgo Bioworks Holdings, Inc. shares will continue growing at the average yearly rate as they did in the last 10 years.

Should I buy or sell Ginkgo Bioworks Stock? Ginkgo Bioworks holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Ginkgo isn't yet profitable on an operational basis. But as its biofoundry gains more customers, more programs, and more throughput, it could be able to drive its costs of servicing each program downward.

Ginkgo Bioworks Holdings (DNA)

Genetic engineering biotech Ginkgo Bioworks Holdings (NYSE:DNA) is another of the Cathie Wood stocks to watch. After her last purchase of nearly 5 million shares, Wood's ETFs own a combined 169 million shares. That makes the biotech her 16th largest position.

Who is Ginkgo Bioworks merging with? ›

BOSTON, April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced the acquisition of AgBiome's platform assets, including over 115,000 fully sequenced and isolated strains, over 500 million unique gene sequences, and ...

Total debt on the balance sheet as of December 2023 : $0.24 B. According to Ginkgo Bioworks 's latest financial reports the company's total debt is $0.24 B. A company's total debt is the sum of all current and non-current debts.

Once thought to be extinct by some researchers in the West, the ginkgo is native to China and now has made its way around the world. Ginkgo is often called a living fossil because it has remained essentially unchanged for 200 million years and can be found in the fossil record at the same time as the dinosaurs.

Ginkgo has been a part of traditional Chinese medicine for centuries. The leaves were used to treat brain and circulatory problems and respiratory conditions. Ginkgo nuts were used for cough, fever, diarrhea, toothaches, and even gonorrhea. It's now sold mostly as a supplement for memory support or brain health.

Ginkgo makes money through a combination of upfront fees, milestone payments, and royalties. Lofty Wall Street estimates regarding its future involve the eventual realization of heaps of downstream revenue from third parties.

2.01 (132.33%) Estimated share price by April 17, 2025.

Largest shareholders include Baillie Gifford & Co, ARK Investment Management LLC, Viking Global Investors Lp, Vanguard Group Inc, ARKK - ARK Innovation ETF, BlackRock Inc., Anchorage Capital Group, L.L.C., Nikko Asset Management Americas, Inc., Sumitomo Mitsui Trust Holdings, Inc., and ARKG - ARK Genomic Revolution ETF ...

Helix Energy Solutions Group's analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.

Is CRSP a Buy, Sell or Hold? Crispr Therapeutics AG has a conensus rating of Moderate Buy which is based on 10 buy ratings, 5 hold ratings and 2 sell ratings.